{"id":"dupilumab-prefilled-syringe","safety":{"commonSideEffects":[{"rate":"20–25","effect":"Injection site reactions"},{"rate":"10–15","effect":"Conjunctivitis"},{"rate":"8–12","effect":"Headache"},{"rate":"5–10","effect":"Nasopharyngitis"},{"rate":"1–3","effect":"Herpes simplex infection"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"By antagonizing IL-4 receptor alpha, dupilumab suppresses the IL-4 and IL-13 pathways that drive type 2 inflammatory responses. This reduces production of IgE antibodies, eosinophil recruitment, and other hallmarks of allergic and atopic inflammation. The mechanism is effective across multiple type 2-mediated conditions including atopic dermatitis, asthma, and allergic rhinitis.","oneSentence":"Dupilumab is a monoclonal antibody that blocks the IL-4 receptor alpha subunit, inhibiting signaling of IL-4 and IL-13 cytokines involved in type 2 inflammation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:45:09.743Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Moderate-to-severe atopic dermatitis"},{"name":"Moderate-to-severe asthma with type 2 inflammation"},{"name":"Chronic rhinosinusitis with nasal polyps"},{"name":"Allergic rhinitis"},{"name":"Eosinophilic esophagitis"}]},"trialDetails":[{"nctId":"NCT07309614","phase":"PHASE3","title":"A Study Assessing the Effect of Dupilumab on Inducing Clinical Remission in Asthma","status":"RECRUITING","sponsor":"Université de Sherbrooke","startDate":"2026-01-29","conditions":"Asthma Control","enrollment":150},{"nctId":"NCT04394351","phase":"PHASE3","title":"Study to Investigate the Efficacy and Safety of Dupilumab in Pediatric Patients With Active Eosinophilic Esophagitis (EoE)","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2020-09-01","conditions":"Eosinophilic Esophagitis (EoE)","enrollment":102},{"nctId":"NCT05575037","phase":"PHASE2","title":"Mechanisms of Benefit of IL4RA Inhibition in Aspirin-Exacerbated Respiratory Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2023-08-01","conditions":"Nasal Polyps, Asthma, Aspirin-Induced, Aspirin-Exacerbated Respiratory Disease","enrollment":17},{"nctId":"NCT04988022","phase":"PHASE4","title":"Dupilumab in the Treatment of Keloids","status":"COMPLETED","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2021-05-25","conditions":"Keloid","enrollment":44},{"nctId":"NCT04442269","phase":"PHASE2","title":"Investigating Treatment With Dupilumab in Patients With Allergic Bronchopulmonary Aspergillosis (ABPA) (LIBERTY ABPA AIRED)","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2020-09-15","conditions":"Allergic Bronchopulmonary Aspergillosis","enrollment":62},{"nctId":"NCT05094570","phase":"PHASE4","title":"Interleukin-4Ra Blockade by Dupilumab Decreases Staphylococcus Colonization and Increases Microbial Diversity in CRSwNP","status":"RECRUITING","sponsor":"University of Virginia","startDate":"2022-09-01","conditions":"Nasal Polyps, Staphylococcus Aureus","enrollment":20},{"nctId":"NCT06614907","phase":"PHASE1","title":"A PhaseⅠ Comparative Study to Evaluate the Pharmacokinetics of QL2108 to Dupixent®","status":"COMPLETED","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2024-08-31","conditions":"Atopic Dermatitis","enrollment":198},{"nctId":"NCT04596189","phase":"PHASE4","title":"Dupilumab for Prevention of Recurrence of CRSwNP After ESS","status":"COMPLETED","sponsor":"Centre hospitalier de l'Université de Montréal (CHUM)","startDate":"2021-05-25","conditions":"Chronic Rhinosinusitis With Nasal Polyps","enrollment":30},{"nctId":"NCT04244006","phase":"PHASE2, PHASE3","title":"A Pilot Study of the Efficacy and Safety of Dupilumab Versus Placebo in Patients With Netherton Syndrome","status":"UNKNOWN","sponsor":"University Hospital, Toulouse","startDate":"2020-07-23","conditions":"Netherton Syndrome","enrollment":24},{"nctId":"NCT03620747","phase":"PHASE3","title":"Continuation of TRAVERSE- LTS12551 Evaluating Dupilumab Safety in Patients With Asthma (Long-Term Follow-Up)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2018-08-30","conditions":"Asthma","enrollment":393},{"nctId":"NCT04358224","phase":"PHASE4","title":"The Utility of Functionally Relevant Signature Genes in Assessing the Clinical Outcomes of Dupilumab Treatment","status":"COMPLETED","sponsor":"Jonathan A. Bernstein, MD","startDate":"2020-09-01","conditions":"Atopic Dermatitis, Eczema","enrollment":12},{"nctId":"NCT03884842","phase":"PHASE3","title":"Dupilumab on Airway Hyper-responsiveness and Ventilation Heterogeneity in Patients With Asthma.","status":"COMPLETED","sponsor":"McMaster University","startDate":"2019-07-01","conditions":"Asthma","enrollment":24},{"nctId":"NCT03359356","phase":"PHASE2","title":"Treatment of Alopecia Areata (AA) With Dupilumab in Patients With and Without Atopic Dermatitis (AD)","status":"COMPLETED","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2018-01-09","conditions":"Alopecia Areata","enrollment":60},{"nctId":"NCT03983460","phase":"NA","title":"Dupilumab Impact on Skin Resident Memory T Cells","status":"UNKNOWN","sponsor":"Association pour la Recherche Clinique et Immunologique","startDate":"2020-03-09","conditions":"Atopic Dermatitis","enrollment":20},{"nctId":"NCT03050151","phase":"PHASE1","title":"Study of Dupilumab Auto-injector Device When Used by Patients With Atopic Dermatitis","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2017-02-28","conditions":"Atopic Disorders, Eczema, Atopic","enrollment":176}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["dupixent","DUPIXENT"],"phase":"marketed","status":"active","brandName":"Dupilumab Prefilled Syringe","genericName":"Dupilumab Prefilled Syringe","companyName":"Jonathan A. Bernstein, MD","companyId":"jonathan-a-bernstein-md","modality":"Biologic","firstApprovalDate":"","aiSummary":"Dupilumab is a monoclonal antibody that blocks the IL-4 receptor alpha subunit, inhibiting signaling of IL-4 and IL-13 cytokines involved in type 2 inflammation. Used for Moderate-to-severe atopic dermatitis, Moderate-to-severe asthma with type 2 inflammation, Chronic rhinosinusitis with nasal polyps.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":3,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}